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Pharmacological Treatment Following
Traumatic Bereavement: A Case Series
JOANNE CACCIATORE and KARA THIELEMAN
School of Social Work, Arizona State University, Phoenix, Arizona, USA
There is little evidence to guide the use of psychotropic medications
immediately following bereavement. This article presents a review
of the relevant literature, followed by a case series on the use of
psychotropic medication in traumatically bereaved individuals.
Of 20 active subjects, nine had been prescribed psychotropic medi-
cation in the days and weeks following a traumatic loss. The
amount, type, and timing of medication in this sample is explored
and compared to the extant literature. Results suggest that clinical
practice may not be guided by empirical research in this area.
It has long been recognized that experiencing the death of a loved one is an
inevitable part of the human experience. Grief is the normal, though painful,
response to such a loss, but there is a great deal of variation in the duration,
expression, and intensity of grief. Although the majority of bereaved indivi-
duals do not require formal intervention to help them cope with grief
(Neimeyer & Currier, 2009), a small number of mourners continue to experi-
ence difficulties that may merit clinical attention. There are various opinions
on how to characterize such difficulties. Some argue for using the existing
DSM-IV diagnoses of posttraumatic stress disorder (PTSD) and major depress-
ive disorder (MDD) (Bonanno et al., 2007). Others argue that grief is distinct
from these disorders and that symptoms associated with intense and pro-
longed grieving are better characterized as prolonged grief disorder (Prigerson
et al., 2009). Among those at risk of experiencing symptoms of prolonged grief
are those who have experienced traumatic bereavement. Traumatic bereave-
ment encompasses deaths that are sudden, violent, or due to human actions
(Green, 2000), as well as the death of a child (Rando, 1985).
Received 18 September 2011; accepted 20 October 2011.
Address correspondence to Joanne Cacciatore, Arizona State University, School of
Social Work, 411 N. Central Avenue, 8th Floor, Phoenix, AZ 85004, USA. E-mail: joanne.
cacciatore@asu.edu
Journal of Loss and Trauma, 17:557–579, 2012
Copyright # Taylor & Francis Group, LLC
ISSN: 1532-5024 print=1532-5032 online
DOI: 10.1080/15325024.2012.688699
557
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 G
eo
rg
ia]
 at
 07
:13
 04
 Ja
nu
ary
 20
13
 
There appears to be a high rate of PTSD and MDD following traumatic
bereavement. A 1998 study of PTSD and bereavement (Zisook,
Chentsova-Dutton, & Shuchter, 1998) found that 45% of individuals met
criteria for PTSD 2 months after the death of a spouse, using measures that
approximated PTSD. At 25 months, 7% met criteria for this disorder. Among
the group bereaved by sudden unexpected death (accident or suicide), 36%
met the criteria. This study reported that 99% of individuals who met the
criteria for PTSD also met the criteria for depression, underscoring the high
rates of comorbidity among these two disorders. Studies of bereaved spouses
have reported that a major depressive episode occurs in about a third of
cases 1 month after the loss, and in about 15% of cases at 13 months after
the loss (Reynolds et al., 1999). Research into prolonged grief, a category that
encompasses many traumatically bereaved individuals, has also addressed
this issue. Studies have estimated that prolonged grief co-occurs with PTSD
in 30% to 50% of individuals, and co-occurs with depression in 21% to
54% of individuals (Shear, Frank, Houck, & Reynolds, 2005).
While psychotropic medications are widely used to treat depression and
posttraumatic stress, there is little research on their use with the recently
bereaved. The purpose of this article is to investigate the use of psychotropic
medications in a traumatically bereaved sample through the use of a case
series. Specific areas to be addressed include the number, type, and timing
of medications. The findings are then compared to the extant literature. There
is some concern that, in the absence of formal guidelines, psychotropic med-
ications are being used improperly with the traumatically bereaved. Because
bereavement-related difficulties are often classified under depression and
posttraumatic stress disorder, the next two sections provide an overview of
relevant research into the use of psychotropic medications for these disorders.
PHARMACOLOGICAL TREATMENT OF
BEREAVEMENT-RELATED DEPRESSION
While there is some evidence that pharmacological treatments may decrease
symptoms of depression that may be present following bereavement, there
is no clear evidence that they actually decrease symptoms of grief (Forte, Hill,
Pazder, & Feudtner, 2004; Zhang, El-Jawahri, & Prigerson, 2006). Antidepres-
sants are among the most-studied drugs for treating bereavement-related
depression. Only two randomized controlled trials evaluating the effectiveness
of an antidepressant, nortriptyline, for grief-related symptoms could be found.
In the first, nortriptyline, a tricyclic antidepressant, was used to treat
bereaved individuals after the loss of a family member, most often a spouse
or significant other, though five subjects had lost an adult child (Reynolds
et al., 1999). This study included 80 individuals, age 50 or older, who had also
been diagnosed with a major depressive episode that had begun within 6 to
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12 months of the loss. While nortriptyline, either alone or with interpersonal
therapy, improved depression scores more than interpersonal therapy alone
or a placebo, it had no effect on grief scores, which improved equally across
groups (Reynolds et al., 1999). Subsequently, 27 of these subjects who
responded either to the drug or placebo were enrolled in a randomized
controlled trial of nortriptyline on EEG sleep measures (Taylor et al., 1999).
Nortriptyline was found to decrease REM sleep time and increase REM
density, while no such changes were observed in placebo responders. How-
ever, upon discontinuation of the drug, EEG sleep measures reverted to
pre-treatment baseline, though both groups reported continued sleep quality
improvement and remission of depression was maintained. Throughout the
study, both groups scored similarly onmeasures of sleep quality and depressive
symptoms. These two studies suggest that nortriptyline had little effect on grief.
In addition, four open trials of antidepressants have been conducted, all
of which found that symptoms of depression were reduced to a greater extent
than symptoms of grief. The first study was of desipramine, a tricyclic, with
participants who met criteria for depression according to the DSM-III, though
the average time since the loss was not reported (Jacobs, Nelson, & Zisook,
1987). The second was of paroxetine, a selective serotonin reuptake inhibitor
(SSRI), conducted with participants displaying traumatic grief an average of 17
months after the loss (Zygmont et al., 1998). This study also measured
depressive symptoms. The third was of bupropion, an atypical antidepres-
sant, conducted with participants meeting DSM-IV criteria for depression as
early as 2 months following the death (Zisook, Shuchter, Pedrelli, Sable, &
Deaciuc, 2001). The fourth was of escitalopram, an SSRI, conducted with part-
icipants meeting DSM-IV criteria for depression within 12 months of the loss
(Hensley, Slonimski, Uhlenhuth, & Clayton, 2009). Sixty percent of this
sample also met the criteria for PTSD, and 48% met criteria for complicated
grief. Among these four studies, the majority of participants were female,
and the mean age was 52. Most had lost a spouse or significant other, though
smaller numbers had lost a parent, a child, a sibling, or a grandchild.
All four of these studies reported that depression symptoms decreased
to a greater extent than grief symptoms and concluded that the medications
show promise for treating symptoms of grief. However, none of them took
into account the finding that grief symptoms tend to naturally resolve in time,
even without intervention (Neimeyer & Currier, 2009). In addition, one study
combined drug treatment with psychotherapy for traumatic grief (Zygmont
et al., 1998), making it difficult to determine the impetus for any improve-
ment. Given the limitations noted above, the authors of all four studies called
for randomized controlled trials. However, to date, no such trials for these
drugs in treating grief have been published.
Even though antidepressants are often the first line of treatment for
depression, the evidence on their efficacy is mixed, with some studies
suggesting that SSRIs are no more effective than placebo. In a meta-analysis
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that has provoked much debate, Kirsch and Sapirstein (1998) found that 75%
of drug response is attributable to placebo response. The authors speculate
that the remaining 25% may be due to an active placebo effect rather than
a true drug effect. Such findings call into question the actual effectiveness
of these medications in treating depression. In addition, a 2003 meta-analysis
found that SSRIs ‘‘yield an excess of suicides and suicide attempts on active
treatments compared with placebos’’ (Healy, 2003, p. 71). Studies using
healthy volunteers have also shown increased suicidality, suggesting that
there may be considerable dangers in using SSRIs (Healy, 2003).
In addition to antidepressants, benzodiazepines have been trialed for
treating bereavement, with somewhat discouraging results. The only rando-
mized controlled study to date, on diazepam, found no effect for the drug
(Warner, Metcalfe, & King, 2001). In fact, the placebo group actually reported
fewer problems with sleep disruptions and nightmares, classic symptoms in a
PTSD subscale. The authors concluded that, at best, benzodiazepines have a
neutral effect (Warner et al., 2001).
However, other studies suggest that the practice of prescribing benzo-
diazepines shortly after bereavement appears to be common, despite the lack
of demonstrated efficacy and concern about long-term use and dependence.
For instance, 49% of obstetricians surveyed endorsed using sedatives, such as
benzodiazepines, to treat bereavement following a stillbirth (Gold, Schwenk,
& Johnson, 2008). In a separate survey of bereaved parents, 41% reported
being prescribed sedatives after the loss of their young child (Harper &
Wisian, 1994). While this study did not evaluate the effectiveness of the med-
ications, bereaved parents generally found the prescription of medication
less helpful than other actions taken by their doctors, such as providing
medical information or psychoeducation, compassionate care, social sup-
port, or grief counseling. In a survey of physicians on their use of benzodia-
zepines in elderly adults, Cook, Biyanova, and Marshall (2007) found that 18
out of 33 physicians spontaneously reported using them to treat bereavement
shortly after a death. This study also found that 20% of elderly adults sur-
veyed had continued to take the drugs long term, some up to 10 years later.
The authors report that the interviews indicated that physicians prescribed
benzodiazepines in an effort to reduce the suffering of their patients follow-
ing a loss. The authors caution that this apparently widespread practice may
be unnecessarily exposing grievers to inappropriate, and potentially harmful,
treatment (Cook et al., 2007).
PHARMACOLOGICAL TREATMENT OF
POSTTRAUMATIC STRESS DISORDER
Some bereaved individuals may meet the criteria for PTSD, especially if the
death was traumatic. Medication is frequently used to target a variety of
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symptoms, including insomnia, psychosis, and excessive anger and arousal
(Cooper, Carty, & Creamer, 2005). Though many types of medication are
used, currently only two drugs have been approved by the Food and Drug
Administration (FDA) for the treatment of PTSD: sertraline and paroxetine,
both SSRIs (Davis, Frazier, Williford, & Newell, 2006). There is mixed
evidence from randomized controlled trials for the efficacy of fluoxetine,
another SSRI (Hertzberg, Feldman, Beckham, Kudler, & Davidson, 2000;
Martenyi, Brown, & Caldwell, 2007; Martenyi & Soldatenkova, 2006). There
is also some support from randomized controlled trials for venlafaxine, a
serotonin-norepinephrine reuptake inhibitor (Davidson et al., 2006); imipra-
mine, a tricyclic antidepressant (Kosten, Frank, Dan, McDougle, & Giller,
1991); phenelzine, a monoamine oxidase inhibitor (Kosten et al., 1991);
and lamotrigine, an anticonvulsant (Hertzberg et al., 1999), in treating differ-
ent aspects of the disorder. There is also some evidence of efficacy for
mirtazapine, a tetracyclic antidepressant, from a pilot randomized controlled
trial (Davidson et al., 2003) and for the antipsychotics risperidone (Padala
et al., 2006) and olanzapine (Stein, Kline, & Matloff, 2002) in various popula-
tions from controlled trials. However, none of these studies focused primarily
on bereaved individuals.
Studies of benzodiazepines have generally shown no effect on PTSD
symptoms and suggest that they do not have a preventative effect when used
shortly after a trauma, though they may help reduce generalized anxiety
(Cooper et al., 2005). In one study of clonazepam and alprazolam, adminis-
tered to trauma victims between 2 and 18 days after the trauma, themedication
group was found to have higher rates of PTSD than the placebo group at a
6-month follow-up, though the authors refrained from concluding that the
drug was responsible for this difference (Gelpin, Bonne, Peri, Brandes, &
Shalev, 1996). Overall, the evidence for medications is, at best, mixed, and
exposure therapy remains the only treatment identified by the Institute of
Medicine (2007) as having sufficient evidence to support its efficacy.
One limitation of pharmacological treatment for PTSD is that when the
treatment is discontinued the symptoms often recur (Cooper et al., 2005). A
combination of pharmacological and psychotherapeutic interventions may
be the best approach in some cases, though evidence is limited (Cooper
et al., 2005). In general, the research on pharmacological treatment for PTSD
is limited by small sample sizes, use of predominantly female sexual assault
survivors or male veteran populations, and differences due to type of trauma
(Cooper et al., 2005). For instance, SSRIs appear to be less effective in veteran,
as compared to civilian, populations (Davidson & van der Kolk, 2007). In
addition, most studies exclude individuals with comorbid substance abuse,
which is common in PTSD (Cooper et al., 2005). As in drug trials for
depression, drug trials for PTSD show a high placebo response rate, and there
is the risk of serious side effects with pharmacotherapy (Cooper et al., 2005).
While pharmacotherapy may be effective once psychopathology has been
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established, there is little evidence to support its use immediately after a
trauma in an attempt to prevent the development of further problems. Instead,
it is recommended that medication be used prudently with individuals not
demonstrating a normal pattern of recovery (Cooper et al., 2005). However,
because few studies have been conducted primarily with bereavement-related
PTSD, the generalizability of this body of knowledge is limited.
Although only two medications have obtained FDA approval, a variety
of drugs are used to treat PTSD in practice. In a study of over 10,000 pri-
vately insured Americans diagnosed with this disorder, the authors con-
cluded that the choice of pharmacological treatment does not appear to
be determined entirely by diagnosis (Harpaz-Rotem, Rosenheck, Mohamed,
& Desai, 2008). This study found that 60% of those diagnosed with PTSD
were prescribed medications. Among those treated with medications in
their sample, 74.3% were prescribed antidepressants, 73.7% were pre-
scribed anxiolytics or sedatives, and 21.3% were prescribed antipsychotics,
with many individuals being prescribed more than one class of medication.
There were also high rates of comorbidity with depression and other disor-
ders, and in cases where more than one diagnosis was listed, the authors
were unable to determine which was the primary diagnosis. However,
16.2% of individuals prescribed antipsychotics did not have a comorbid
diagnosis of bipolar disorder or schizophrenia, the only approved indica-
tions for these medications. The authors expressed concern at the off-label
(not approved by the FDA) usage of this class of medication and
speculated that clinicians may be targeting specific symptoms with various
medications (Harpaz-Rotem et al., 2008).
METHODS
Design
This is a case series on the current use of psychotropic medication in the trau-
matically bereaved. This study utilizes a cross-sectional record review of
subjects receiving counseling services within a 90-day period.
Instruments
The 25-item Hopkins Symptom Checklist (HSCL) is a modification of the
58-item HSCL originally developed by Parloff, Kelman, and Frank (1954)
and adapted by many subsequent researchers (Derogatis, Lipman, Rickels,
Uhlenhuth, & Covi, 1974). This instrument is a self-report questionnaire that
measures anxious and depressive symptoms. The overall score is divided
by 25 (number of items) to provide a mean score. It has demonstrated an
86.7% concordance rate with physician assessments of global psychopath-
ology in primary health care settings (Hesbacher, Rickels, Morris, Newman,
562 J. Cacciatore and K. Thieleman
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& Rosenfeld, 1980) and is considered to be adequate for screening for psychi-
atric disorders (Veijola et al., 2003). Studies have identified different cutoff
points for mean scores to denote significant symptoms, ranging from 1.55
to 1.75 (Veijola et al., 2003) in various populations. Given the intensity of
symptoms often observed in traumatic bereavement, the current study uses
the higher cutoff point of 1.75.
The second intake instrument is the Impact of Event Scale-Revised
(IES-R), developed by Weiss and Marmar (1997), which measures traumatic
stress responses along three subscales: hyperarousal, intrusion, and avoid-
ance. This self-report questionnaire has demonstrated high internal consist-
ency (alpha¼ 0.96) (Creamer, Bell, & Failla, 2003), high test-retest reliability
(alpha¼ .89 to .94), and good predictive validity (Weiss & Marmar, 1997).
The total score is divided by 22 (number of items) to obtain a mean score.
Though the developers did not specify a standard cutoff point (Weiss,
2004), a mean score of 1.5 or higher is generally accepted as indicating signifi-
cant trauma symptoms (Creamer et al., 2003). Separate subscale scores were
not used for the current study. Though not direct measures of grief, these two
instruments measure symptoms commonly seen in traumatic bereavement,
namely depressive, anxious, and traumatic stress symptoms.
Procedure
The location of the study is a mental health agency that serves individuals and
families who have experienced a traumatic death. Counseling is offered on
a sliding scale or ability-to-pay basis. Counseling is delivered vis-a`-vis
mindfulness-based counseling techniques, as well as narrative and logo
therapy. The subjects in the case series differed as to the length of time they
remained in treatment. Since this study does not consider outcomes or the
effect of therapy, only the use of psychotropic medication, all subjects who
completed the intake instruments and were seen by a therapist at least once
were included. This includes subjects with a previous psychiatric history so
long as medication was newly prescribed following the death. The aim is sim-
ply to provide a comprehensive overview of the types of prescribing patterns
observed in this sample, including factors that may have influenced these
patterns. No attempt is made to gauge the impact of counseling on subjects.
The dosage of medications is included when it was reported by the subject
or contained in documents obtained from other sources.
Permission to review files was obtained from the participants following
institutional review board approval. Consent was obtained from subjects
whose information is presented in the case series. All information presented
in the series was obtained from the subjects’ files at the mental health agency.
In some cases, information from outside sources (i.e., hospital, counselor) was
included in the chart. Unless otherwise noted, all information included was
reported by the subject to his or her therapist and documented in the chart.
Pharmacology and Grief: Case Series 563
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 G
eo
rg
ia]
 at
 07
:13
 04
 Ja
nu
ary
 20
13
 
Subjects
The charts of all active subjects who completed intake measures (n¼ 20) were
reviewed. ‘‘Active subjects’’ are defined as subjects over the age of 18 years
who had been seen within 90 days of data collection. All subjects had experi-
enced a traumatic death and were self-referred for grief-specific counseling.
Of these 20, nine charts mentioned the use of psychotropic medication fol-
lowing the loss. None of the prescribing was done at the counseling agency.
Of the nine subjects who had taken medications, six were female and
three were male, with a mean age of 39.1 years and a range of 23 to 58 years.
Seven subjects experienced the deaths of children, ranging in age from
stillbirth to 26 years. One subject experienced unexpected conjugal death,
and another experienced the unexpected death of a sibling. Two of nine case
study subjects had a previous psychiatric history noted in the chart. One sub-
ject was diagnosed in early grade school with attention deficit hyperactivity
disorder (ADHD) and had received prior psychiatric treatment for this
disorder. The other subject’s chart contained hospital records showing a
history of postpartum depression.
RESULTS
The charts of the nine subjects who used psychotropic medications and the 11
subjects who were not taking psychiatric medications were reviewed to deter-
mine if there were any noticeable differences in measures or symptoms. The
two groups were similar on a number of variables, contained in Table 1. The
cases of each of the nine subjects who had taken themedication are summarized
in Table 2. The majority of subjects in both groups were female, White, and had
lost a child. Both groups had a similar mean age at intake and mean time from
the loss to intake at the agency. No one in the unmedicated group had a previous
psychiatric history noted in the chart. In both groups, all subjects met both instru-
ment cutoff points for significant depressive, anxious, and trauma symptoms. On
average, subjects who took medications had slightly higher scores on both
instruments at intake than those who did not take medications, indicating more
self-reported distress in this group. The mean score for the medicated group on
the IES-R (n¼ 9) was 2.6, while the mean score for the unmedicated group
(n¼ 11) was 2.41. The mean score on the HSCL for the medicated group was
2.98, while the mean score for the unmedicated group was 2.33. It is possible
that the subjects who received medication had more severe symptoms, that
medication somehow led to greater symptom levels, or that there is another
explanation. Though this finding is interesting, no inferences can be drawn from
it due to the small, nonrandom sample used in this case series. Overall, based on
clinical impressions, the two groups of subjects were similar to each other
in terms of biopsychosocial symptomatology, such as sleep disruption, hyper-
arousal, and the expression of painful emotional states.
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This review focuses on the features of subjects who had taken medica-
tions. Below is a description of each of the nine subjects who had used
psychotropic medications since experiencing a traumatic death (details have
been slightly augmented to protect subject anonymity).
Case 1
This subject, a woman in her mid-50s, is a mother of two who experienced
the death of her son in his mid-20s to suicide. Six months prior to his death,
her son was diagnosed with depression and prescribed psychotropic
medications by his general physician, which she identified as escitalopram
and lithium. The subject noticed a slight improvement in his affect for about
1 month, then a gradual decline, including what she described as ‘‘blatantly
bizarre and erratic’’ behaviors, which culminated with his suicide. Within 2
weeks of his death, her family physician referred her to a psychiatrist due
to her apparent emotional distress. The subject reported that the psychiatrist
diagnosed depression and first prescribed escitalopram, which she refused to
take, as this was one of the drugs prescribed to her son prior to his suicide.
She was then prescribed paroxetine, 25mg per day. After a brief period of
time on this medication, she experienced ‘‘a bad reaction,’’ including
thoughts of self-harm, at which time her prescription was changed to
trazodone, 150mg twice a day, and dextroamphetamine=amphetamine,
25mg once a day. She remained on the medications for several weeks and
TABLE 1 Comparison of Unmedicated and Medicated Subjects.
Unmedicated
(n¼ 11)
Medicated
(n¼ 9)
Mean intake IES-R score 2.41 2.6
Mean intake HSCL score 2.33 2.98
Mean age at intake 40.6 39.1
Gender (%)
Male 18 33
Female 82 67
Ethnicity (%)
White 91 78
Hispanic 9 11
Asian 0 11
Average time from death to intake (months) 14.5 14.7
Relationship to deceased (%)
Parent 82 78
Sibling 0 11
Spouse 18 11
Prior psychiatric history noted in chart (%) 0 22
Met threshold for probable PTSD
(IES-R score >1.5) (%)
100 100
Met HSCL threshold for anxiety and depression
(HSCL score >1.75)
100 100
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‘‘didn’t like the way they were feeling,’’ so she took herself off both medica-
tions. She began counseling at the agency 21 months after her son’s death.
Upon intake, her IES-R score was 2.77 and her HSCL score was 3.36.
Case 2
This subject, a mother of two in her early 30s, experienced the death of her
baby at a caregiver’s home. Seven days later, her physician prescribed
sertraline, 50mg. One week later it was increased to 100mg, and then to
150mg. Three weeks after that, she was also prescribed alprazolam, .25mg
twice per day, with venlafaxine, 112.5mg daily, prescribed at a subsequent
time. This subject has a history of postpartum depression and past treatment
with escitalopram, sertraline, bupropion, and venlafaxine noted in hospital
records included in her chart. She had one family and individual crisis intake
meeting with the clinician nearly 1 month following her baby’s death, wherein
she reported ‘‘pacing the house at night’’ and recurrent nightmares. She failed
to make her next appointment the following week and did not return repeated
phone calls to the clinician. Two months later, the subject’s psychiatrist called
the clinic from an inpatient facility where she had been hospitalized for 3
weeks due to suicidal ideation. During her stay in the inpatient facility, the
subject reported repeated visual hallucinations and increasing nightmares.
Hospital records showed the following diagnoses: mood disorder NOS,
PTSD, and a V-code for bereavement. There was also a note to ‘‘rule out’’ non-
psychotic bipolar disorder in her hospital chart, though the final diagnosis was
not specified. She was offered electroconvulsive therapy, which she refused,
as she did not want to lose any memories of her child. She was released to the
care of the clinic 4 weeks following admission. The subject reported being
prescribed the following medications, in various combinations, since her
admission to the hospital: lithium, 450mg in the morning and 900mg at night;
valproic acid, 1,000mg in the morning and 1,500mg at night; haloperidol,
1mg four times per day; quetiapine, 600mg at night; mirtazapine, 30mg at
night; venlafaxine, 150mg per day; zolpidem, 10mg at night; lorazepam,
1mg every 6 hours; and clonazepam, 1mg four times per day. In addition,
she was taking benztropine, 1mg twice per day, in order to manage the side
effects of the psychotropic medications, as well as medication for health con-
ditions. She began biweekly counseling sessions at the agency and, under
medical supervision, weaned herself off medications during the 2 months fol-
lowing the hospital discharge. Upon her initial intake at the clinic, her IES-R
score was 3.68, and her HSCL score was 3.76.
Case 3
This subject is a woman in her early 20s who experienced the death of her first
child during birth. She was given lorazepam during labor and birth, which she
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says ‘‘helped to calm’’ her because she was ‘‘hysterical and screaming and
crying a lot.’’ Prior to her hospital discharge, the obstetrician prescribed
50mg of sertraline. The subject claimed she wanted to wean herself off the
medication because she ‘‘can’t feel’’ when taking it. She began counseling 3
months following the death of her baby. On intake, her IES-R score was
2.18 and her HSCL score was 3.28. This subject only attended two sessions
when she relocated out of the area.
Case 4
This subject is a woman in her late 50s. Her only child, a teenager, was killed
in a car accident. Approximately 7 to 8 weeks later, she was prescribed
citalopram, 20mg, by her physician. Approximately 3 to 4 months after this,
the subject was diagnosed with adjustment disorder with mixed anxiety and
depressed mood by a counselor. She began counseling at the current agency
13 months later. At intake, her IES-R score was 2.36 and her HSCL score was
2.56. This subject relocated out of the area after attending two counseling
sessions and was still taking the medication at termination.
Case 5
This subject is a father of four in his late 30s whose adolescent child died sud-
denly from a brain hemorrhage of unknown etiology. Later that same day, his
physician prescribed alprazolam, .5mg twice per day, and venlafaxine, 75mg
once per day. Within 6 months, the physician added zolpidem, 10mg once
per day. The medications have been adjusted since the death. At the time
of data collection, the subject was under the care of a psychiatrist for
medication management. Documents obtained from outside sources, and
contained in the chart, show diagnoses of polysubstance dependence, recur-
rent, moderate major depressive disorder, and PTSD, as well as a V-code for
bereavement, all given subsequent to his child’s death. At the time of intake,
this subject reported he was self-medicating with alcohol. He began intensive
counseling 14 months following the death. At intake, his IES-R score was 3.09
and his HSCL score was 3.48. He stopped taking all of his psychotropic
medications after 16 sessions while under medical supervision.
Case 6
This subject is a man in his early 20s whose sibling died following an accident.
The subject was in his late teens at the time of the death. He was diagnosed
with ADHD during grade school and prescribed methylphenidate, which he
continued to take through high school. He was not taking any psychotropic
medications when the death occurred. Within 1 week of the death, the subject
was prescribed paroxetine and clonazepam by his general physician. He was
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subsequently prescribed methylphenidate, triazolam, and bupropion. At
intake, the subject was taking paroxetine and clonazepam as prescribed by
a psychiatrist. He began counseling 4.5 years after his sibling’s death. At
intake, he had been unable to leave his home for nearly a year. His intake
IES-R score was 2.23 and his HSCL score was 3.4. Under medical supervision,
he began weaning himself off medications after 16 counseling sessions and
remains off all medications.
Case 7
This subject is a woman in her early 40s whose spouse died traumatically of a
sudden-onset illness. The subject was prescribed 12.5mg of quetiapine by her
physician 3 weeks after her husband’s death. She experienced an ‘‘extreme
reaction’’ to the medication, at which point her prescription was changed to
fluoxetine, 5mg once per day. Again, she experienced a reaction to the drug,
and 1 month later her prescription was changed to sertraline, 12.5mg per day.
Two weeks later, she was switched back to quetiapine at 10mg per day. The
next month, she was prescribed mirtazapine, 3.75mg per day. Five months
after her spouse’s death, the prescription was changed to bupropion and
temazepam. This subject noted she was very sensitive to medications and
had only wanted them in small doses. She claimed she ‘‘felt significantly more
depressed,’’ and later that month she had a serious suicide attempt requiring
hospitalization. She discontinued the medications within 2 months of hospital
discharge and was not taking any medications at intake 16 months after the
death. Her intake IES-R score was 2.5 and her HSCL score was 2.44.
Case 8
Cases 8 and 9 represent a married couple who were seen for both individual
and couple’s grief counseling. Their second child was stillborn at 40-plus
weeks gestation and died as a result of a traumatic birth injury. Case 8, the
child’s mother, is in her late 30s and has one other child, age 2. She was given
a single dose of lorazepam and was prescribed clonazepam, 1mg, and fluox-
etine, 20mg, while in the hospital by her obstetrician, on the same day of the
baby’s death. Her intake IES-R score, 2 months after the infant’s death, was
2.05 and her HSCL score was 2.4. This subject was continuing to take the
medication at last contact.
Case 9
This subject, in his late 30s, is the husband of the subject presented in Case 8.
He was prescribed escitalopram by his general physician, 20mg once per
day, 3 weeks following his baby’s death after he reported having difficulty
focusing on running his family business. Upon intake at 2 months after the
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death, his IES-R score was 2.5 and his HSCL score was 2.16. He was continu-
ing to take the medication at last contact.
DISCUSSION
This case series sought to investigate the amount, type, and timing of psycho-
tropic medications in a small sample of traumatically bereaved individuals. A
review of subject records at the study agency found that nine of 20 indivi-
duals (45%) had been prescribed medications in the 2 months following a
traumatic death. Three subjects (33%) were given medications the same
day as the loss, while two more (22%) were given medications within a
week. In these five cases, an antidepressant (most often an SSRI) was given,
sometimes in conjunction with a benzodiazepine. In an additional three
cases (33.3%), medications were prescribed within 2 to 3 weeks of the loss.
In two cases it was an SSRI, and in one case it was an antipsychotic. In a final
case (11.1%), medication (an SSRI) was prescribed 8 weeks after the loss. In
six cases, the initial prescriber was the subject’s physician, in two cases it was
the obstetrician, and in one case the prescriber could not be determined.
The most commonly prescribed types of medication initially used were
antidepressants and benzodiazepines. Among the five subjects given benzo-
diazepines, three prescriptions were given the same day as the death, one
was given a week after the death, and another was given 3 weeks after the
death. Two of the subjects given prescriptions the same day were women
who had experienced stillbirth, and the prescribing was done by an obste-
trician, which reflects the findings of Gold et al. (2008) that this is a common
practice. The third subject who received a prescription for benzodiazepines
the day of the loss was male, and the prescriber was his physician. Though it
is unlikely that prescribers were attempting to treat specific disorders, it is
possible that they used these medications in an attempt to provide some
relief from the intense suffering experienced by their patients following a
traumatic death. However, research suggests that benzodiazepines are not
effective at preventing the development of problems following a trauma
(Cooper et al., 2005) and should be used with caution.
The increasing use of multiple psychotropic medications has been of
concern to some clinicians and researchers, as many combinations have
not been adequately studied to determine safety and efficacy. This case series
found that a single medication was initially used with five of nine subjects (in
all cases, an antidepressant was prescribed). Two of these subjects had
another medication added within a few weeks. Four subjects were initially
prescribed two medications, which consisted of a benzodiazepine and an
antidepressant. This includes one case in which a single dose of a benzodia-
zepine was used, along with a prescription for an SSRI (Case 3). Overall, five
individuals had medications added after the initial prescription or had their
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initial prescription changed. Additional medications prescribed include
antidepressants of various classes, benzodiazepines, sedatives, stimulants,
lithium, and valproic acid. While the majority of subjects took no more than
two medications at one time, three subjects took at least three medications
concurrently (Cases 2, 5, and 6).
In addition, Case 2 may raise additional concerns regarding the use of
multiple medications. This subject was initially prescribed an SSRI and had
a benzodiazepine added 3 weeks later. She was later switched to a different
class of antidepressant. Upon discharge from an inpatient unit 3 months after
the loss, she indicated that she had taken at least nine psychotropic medica-
tions during her 4-week stay at the facility, including two antipsychotics, two
antidepressants, two benzodiazepines, and a sedative, as well as lithium and
valproic acid. Though it is not clear what specific medication combinations
were used, the high number of medications prescribed is noteworthy, and
hospital records confirm at least five medications being used concurrently.
This case series noted some apparently off-label prescribing of antipsy-
chotic medication. In one case, an antipsychotic was the first medication
prescribed to a subject 3 weeks after the loss (Case 7). This subject indicated
that she had not, to her knowledge, ever been diagnosed with a psychotic or
bipolar disorder, the only diagnoses for which this class of medication is
currently approved. The prescriber’s reason for choosing this class of medi-
cation is unknown. In another instance (Case 2), antipsychotics were used in
conjunction with other medications, including lithium and valproic acid, after
an SSRI and benzodiazepine were not effective. This subject reported hallu-
cinations of hearing her deceased child’s voice, which may have been the
symptom being targeted by the prescriber. However, the subject indicated
that her hallucinations worsened upon treatment with antipsychotics in an
inpatient facility. Records from the facility, included in the subject’s chart,
show a diagnosis of mood disorder NOS, PTSD, and a V-code for bereave-
ment. This subject’s chart indicated a directive to rule out nonpsychotic
bipolar disorder, which may explain the use of some of the medications,
though the final diagnosis was not specified. In both cases, additional
information may have provided a rationale for the use of psychotropic
medications; however, it was not available for this study.
This study did not evaluate outcomes, and thus whether or not subjects
benefited from the use of psychotropic medications remains unknown.
Some subjects continued to take the medications, which may indicate that
they found them to be helpful. However, it is notable that two subjects
(Cases 1 and 7) described adverse reactions to medication, and that one
of them (Case 7) appeared to link a change in medication to worsening
depression, culminating in a suicide attempt. A third subject (Case 3)
described a calming effect of a benzodiazepine the day of the loss but
reported an inability ‘‘to feel’’ while taking an SSRI and wanted to discon-
tinue the medication. The dosages reported by subjects generally fall within
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the typical dose ranges for the medications being used. However, Case 2
reported a higher than usual dose of valproic acid (2,500mg daily), and
Case 7 reported lower than usual doses of quetiapine (10–12.5mg), fluox-
etine (5), and mirtazapine (3.75). While Case 7 reported wanting only very
low dosages, the prescriber’s reasons for utilizing a high dose of valproic
acid in Case 2 are unclear. It is also possible that subjects misreported the
dosage of their medications.
Even though significant differences between grief and depression and
posttraumatic stress have been documented (Lichtenthal, Cruess, & Prigerson,
2004), the overlap in symptoms makes it difficult to determine the best course
of treatment. According to the intake IES-R and HSCL scores, all subjects (in
both the medicated and unmedicated cohorts) were potentially eligible for
a diagnosis of PTSD and a depressive or anxiety disorder, though the etiology
and course of symptoms due to bereavement may be different than for
non-bereavement-related symptoms. For example, a recent longitudinal
epidemiological study (Mojtabai, 2011) found that individuals who experi-
enced single, brief episodes of bereavement-related depression showed
a different symptom profile, fewer comorbid anxiety disorders, and less
impairment in role functioning than individuals who had experienced
non-bereavement-related single, brief episodes. Additionally, those with
bereavement-related depressive episodes had a lower rate of past treatment
than those with other types of depression and showed no increased risk of
future episodes beyond what is found in the general population.
Another epidemiological survey (Gilman et al., 2012) found that
bereavement-related depression, even when severe enough to be diagnosed
as MDD in spite of the bereavement exclusion, was associated with less
severe psychopathology than MDD unrelated to bereavement. Those with
bereavement-excluded MDD, as well as those who qualified for MDD in spite
of bereavement, reported fewer previous psychiatric problems, less
psychosocial impairment and service utilization, fewer depressive episodes,
and a lower rate of subsequent psychiatric disorders over a 3-year period.
Though the validity of the bereavement exclusion has been called into ques-
tion, its planned removal in the DSM-5 (American Psychiatric Association,
2010) may further obscure the differences between bereavement-related and
non-bereavement-related symptoms, potentially leading to hasty or inappro-
priate treatment. Psychotropic medications should be used with care when
symptoms occur in the weeks and months following bereavement, as there
is not yet any compelling evidence to support their use in this population
and little is known about how they may affect the trajectory of grief (Cook
et al., 2007; Spiegel, 2010). Even when a diagnosis of a disorder has been made
following bereavement, research suggests that medication should be only one
component of treatment. For instance, based on a review of more than 500
articles on depression, Malhi et al. (2009) recommended a careful process of
evidence-based intervention. First, ensure subject safety and education and
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establish a therapeutic relationship. Then conduct a thorough assessment, con-
sidering factors that may influence treatment strategy. Finally, in the following
order, utilize psychological and psychosocial therapies, pharmacological
therapy, a combination of both, and electroconvulsive therapy as a last result.
It is important for clinicians to remember that grief, in and of itself, is not
pathological. In addition, research suggests that traumatic death presents a
unique set of emotional responses not found in non-traumatic death, includ-
ing separation distress and prolonged pining (Raphael & Martinek, 1997). The
deaths of children, and other untimely and sudden deaths, have been recog-
nized as an especially traumatic form of loss, to be particularly intense, and to
evoke a wider range of reactions than other types of loss (Rando, 1985). In
such cases, expressions of grief, even if they appear somewhat extreme,
may represent a normal reaction to an especially devastating event. For indi-
viduals who have experienced traumatic bereavement, it may be unrealistic to
expect a resolution of symptoms of grief or of active mourning processes
within the 2-month time period allowed by the DSM-IV before MDD can be
diagnosed or within the 1-month period before PTSD can be diagnosed.
Limitations
This is a small case series at one clinic that treats the traumatically bereaved.
All information in this study was obtained from subject files at one point in
time, so additional information regarding medication use and outcomes is
not available. Two subjects discontinued counseling at the agency, due to
relocation, shortly after intake, so information on their medication usage is
limited. Additionally, two subjects had a prior psychiatric history, which
may have affected a provider’s decision to prescribe medication following
traumatic loss. The subjects in this case series differed from one another in
many ways, including the length of time since the loss to intake at the
agency, relationship to the deceased, circumstances of the loss, and previous
psychiatric history. No attempt was made to gauge the impact of therapy or
to distinguish the effects of therapy from the effects of medications. The aim
was simply to provide a description of the prescribing patterns seen in this
sample and compare them to the relevant literature. Case series are descrip-
tive only, are vulnerable to many limitations such as bias and the absence of a
control group, and are not representative of the general population. No
causal inferences can be drawn from the case series. Nevertheless, the obser-
vations noted in this study may be useful in the design and implementation
of future studies with this population and others.
Clinical Implications
It is often difficult for clinicians to distinguish between normal and patho-
logical bereavement trajectories and reactive and endogenous sadness,
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particularly in the aftermath of traumatic death, as there is often an overlap
in symptoms. More research is needed in this area to ensure that clinicians
do not inadvertently utilize unnecessary or even harmful treatments. Due to
the lack of evidence to support their use, medications should be dispensed
judiciously following traumatic death. Medications may be indicated, poss-
ibly in conjunction with an empirically supported psychosocial inter-
vention, if psychopathology can be clearly established or if a client
specifically requests medications. In that case, there should be informed
consent regarding the potential risks and benefits. Determining a ‘‘normal’’
period of grief in the aftermath of a traumatic loss, such as the death of a
child, is not an easy task. When medications are indicated, prescribers
should follow current evidence-based practices (Raphael, Minkov, &
Dobson, 2001) and choose interventions that pose minimal risk and the
greatest potential benefit to the subject. However, given the lack of efficacy
and the concerns raised by pharmacological treatments, psychosocial inter-
ventions may currently be the safest treatment options following traumatic
bereavement, especially when there is no evidence of prior or concurrent
psychopathology.
Conclusion
Overall, the number of empirically based randomized controlled trials con-
ducted with traumatically bereaved individuals is severely limited, and no
medication has yet demonstrated efficacy for treating grief. In this case series,
medications were found to be frequently used as a first course of treatment
following traumatic bereavement. They were often prescribed very early in
bereavement, sometimes on the same day as the death. There appears to
be little evidence to support this practice, as it is difficult to assess a trajectory
of pathology so quickly after a traumatic loss. The elimination of the
bereavement exclusion in the DSM-5 may lead to an increase in the trend
of prescribing medication for symptoms of grief. This case series noted the
apparent off-label use of antipsychotic medications to treat grief-related
symptoms. Though this was only documented in two subjects, it is worthy
of further investigation to determine how common a practice this is in the
general population as well as to determine the risks and benefits. Also of note
is the finding that three of the nine subjects taking medication described an
adverse reaction, raising additional concerns about the safety and efficacy of
medication early in bereavement.
This case series utilized a small sample, and more research should be
conducted on this population to determine if the trends in the use of psycho-
tropic medication noted here are representative of the traumatically
bereaved. It is concerning that 45% of active agency clients were prescribed
psychotropic medications, often very soon after the death, despite the lack of
evidence to support medicating normal or complicated grief (Cook et al.,
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2007). Only two subjects had a psychiatric diagnosis noted in their charts that
predated the deaths. Because psychopharmacological means, to this point,
have not demonstrated efficacy in treating bereavement, some of the pre-
scribing patterns noted in this case series may not reflect evidence-based
practice. A lack of practice guidelines for working with this population
may contribute to these patterns. The findings of this case series highlight
the need to develop effective bereavement interventions that are evidence
based in both medicine and mental health practice.
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